Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.

Original languageEnglish
Pages (from-to)96-101
Number of pages6
JournalInternational Journal of Cardiology
Volume132
Issue number1
DOIs
Publication statusPublished - 2009 Feb 6

Fingerprint

Vascular Stiffness
Pulse Wave Analysis
Ankle
Fasting
Arm
Blood Pressure
Insulin Resistance
Interleukin-6
Triglycerides
Body Mass Index
Insulin
Inflammation
Glucose
Advanced Glycosylation End Products
R Factors
Adiponectin
Waist Circumference
Diabetes Complications
human esRAGE protein
Type 2 Diabetes Mellitus

Keywords

  • Arterial stiffness
  • Cardiovascular disease
  • esRAGE
  • Inflammation
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

@article{d700ab0f34db40499bc842f3bb3a0200,
title = "Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness",
abstract = "Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.",
keywords = "Arterial stiffness, Cardiovascular disease, esRAGE, Inflammation, Type 2 diabetes",
author = "Choi, {Kyung Mook} and Hye-Jin Yoo and Kim, {H. Y.} and Lee, {K. W.} and Seo, {Ji A} and Kim, {Sin Gon} and Kim, {Nan Hee} and Choi, {D. S.} and Sei-Hyun Baik",
year = "2009",
month = "2",
day = "6",
doi = "10.1016/j.ijcard.2007.10.047",
language = "English",
volume = "132",
pages = "96--101",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness

AU - Choi, Kyung Mook

AU - Yoo, Hye-Jin

AU - Kim, H. Y.

AU - Lee, K. W.

AU - Seo, Ji A

AU - Kim, Sin Gon

AU - Kim, Nan Hee

AU - Choi, D. S.

AU - Baik, Sei-Hyun

PY - 2009/2/6

Y1 - 2009/2/6

N2 - Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.

AB - Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.

KW - Arterial stiffness

KW - Cardiovascular disease

KW - esRAGE

KW - Inflammation

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=58849111810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849111810&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2007.10.047

DO - 10.1016/j.ijcard.2007.10.047

M3 - Article

VL - 132

SP - 96

EP - 101

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -